Preventing anthracycline-induced cardiotoxicity with ivabradine: A systematic review and meta-analysis

doi:10.4330/wjc.v18.i7.121472

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 7

This Article

(18)

(21)

(0)

(214)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Cardiology

ISSN

1949-8462

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Meta-Analysis

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Cardiol. Jul 26, 2026; 18(7): 121472
Published online Jul 26, 2026. doi: 10.4330/wjc.v18.i7.121472

Table 2 Tabulated representation of baseline characteristic of included population, n (%)

Characteristics		*Čiburienė et al[13], 2023*		*Rizk et al[14], 2025*		*Vasyuk et al[15], 2017*
Characteristics		Ivabradine	Placebo	Ivabradine	Placebo	Ivabradine	Placebo
Age (years)		47.8 ± 9.9	48 ± 10.2	49 (32-59)	39 (26-60)	49.8 ± 9.4	48.7 ± 9.5
Female		21 (100)	27 (100)	24 (41)	18 (35.3)	28 (50.0)	4 (16.7)
Cancer type	Breast	21 (100)	25 (92.6)	0	0	23 (100)	32 (100)
	NHL	0	0	30 (58.8)	29 (51.8)	0	0
	HL	0	0	18 (35.3)	26 (46.4)	0	0
	Sarcoma	0	2 (7.4)	3 (5.9)	1 (1.8)	0	0
Anthracyclines commutative dose (mg/m²)	Doxorubicin	236 ± 70	246 ± 69	300 (250-300)	300 (250-300)	441.4 ± 84.5	391.7 +/- 103.8
Anthracyclines commutative dose (mg/m²)	Epirubicin	360 ± 70	360 ± 70	-	-	-	-
Risk factors	HTN	3 (15)	2 (7.4)	13 (25.5)	9 (16.4)	5 (21.0)	9 (28.3)
	DM	0	0	4 (7.8)	5 (8.9)	1 (4.3)	1 (3.1)
	HLD	13 (65)	21 (77.8)	4 (8.0)	3 (5.4)	-	-
	Smoking	1 (5)	6 (22.2)	7 (13.7)	9 (16.4)	-	-
	CKD	0	0	-	-	1 (4.3)	3 (9.4)

NHL: Non-Hodgkins lymphoma; HL: Hodgkins lymphoma; HTN: Hypertension; DM: Diabetes mellitus; HLD: Hyperlipidemia; CKD: Chronic kidney disease.

Full Size Table

Citation: Sohail R, Khattak R, Shah HH, Khan Z, Jawed S, Wasim AU, Akram B, Patel R, Patel S, Alam M, Chaudhry S, Mehdi S, Patel V, Singh M. Preventing anthracycline-induced cardiotoxicity with ivabradine: A systematic review and meta-analysis. World J Cardiol 2026; 18(7): 121472
URL: https://www.wjgnet.com/1949-8462/full/v18/i7/121472.htm
DOI: https://dx.doi.org/10.4330/wjc.v18.i7.121472

Sohail R, Khattak R, Shah HH, Khan Z, Jawed S, Wasim AU, Akram B, Patel R, Patel S, Alam M, Chaudhry S, Mehdi S, Patel V, Singh M. Preventing anthracycline-induced cardiotoxicity with ivabradine: A systematic review and meta-analysis. World J Cardiol 2026; 18(7): 121472 [DOI: 10.4330/wjc.v18.i7.121472]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.